GRI GRI Bio Corporation Price-to-Projected Revenue Ratio
GRI Bio, Inc. (GRI) is developing innovative NKT therapy to combat inflammatory processes and autoimmune disorders. A flexible technological base enables the rapid implementation of new formulas with low production costs. The forward P/S valuation demonstrates capitalization dynamics relative to expected revenues, where the 0.00 indicator determines the metric's magnitude. The results of current clinical trials for anti-fibrotic drugs will serve as a key driver for future demand.
GRI Bio Corporation (GRI) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization data:
- book value of equity indicators:
- debt and solvency information:
- financial results and valuation multiples details:
GRI - Net Financial Result|Expected Profit GRI Bio, Inc.|GRI - Price to Earnings Multiple|Forward P/E Multiple GRI Bio Corp|GRI - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio GRI Bio Corporation|GRI - Operating income before deduction of amortization|Net earnings per share (EPS TTM) GRI Bio|GRI - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months gribio.com|GRI - Earnings per share increase in current year|Earnings growth forecast for next year GRI Bio, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:GRI (GRI Bio)
The continuity of immunoregulator development at GRI Bio, Inc. (GRI) is ensured through the diversification of its contract research organization network and the control of chemical compound supplies. The forward P/S metric compares the current share price with projected revenue, allowing investors to assess the extent of overpayment for expected sales growth or the risk of capital stagnation by analyzing the price action on this chart.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|Projected Price to Revenue BioNTech Inc.|ABVX - Price-to-Projected Revenue Ratio|Forward Price to Sales ADMA (ADMA Corp)|PTGX: Forward P/S Multiple|IMVT - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple KNSA|GRFS: Forward Price to Sales|Forward P/S Multiple ADPT|Price-to-Projected Revenue Ratio CLDX (Celldex Corp)|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Dianthus Therapeutics Inc|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|Nektar Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple UPB (Upstream Bio Corp)|ZBIO - Forward Price-to-Revenue Multiple|IMNM: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio gossamerbio.com GOSS|KALV: Forward P/S Multiple|Projected Price to Revenue Septerna, Inc. SEPN|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Market Cap to Expected Sales Ratio anaptysbio.com|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|ENGN (enGene Holdings Inc) - Future Price to Revenue|RAPT Therapeutics, Inc. - Forward P/S Multiple|Forward Price to Sales JBIO (Aerovate Therapeutics Inc)|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|CABA: Forward Price to Sales|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward P/S Multiple eledon.com ELDN|AGEN: Forward Price-to-Revenue Multiple|Forward Price to Sales CLYM (Climb Bio Inc.)|ZURA: Forward P/S Multiple|ATYR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Forward Price-to-Revenue Multiple Ikena Oncology, Inc. (IMA)|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Connect Biopharma Holdings Limited - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|IFRX (InflaRx N.V.) - Market Cap to Projected Revenue|XFOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio Adicet Bio, Inc. (ACET)|CELU (Celularity Inc) - Forward P/S Multiple|INMB - Projected Price to Revenue|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|KZR (kezarlifesciences.com) - Forward Price to Sales|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio Akari Therapeutics PLC (AKTX)|ENLV: Forward Price-to-Revenue Multiple|Forward Price to Sales QTTB (Q32 Bio Inc.)|GOVX: Forward P/S Multiple|EDSA (edesabiotech.com) - Price-to-Projected Revenue Ratio|IBIO (iBio) - Forward P/S Multiple|Carisma Tx (CARM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|BOLT - Market Cap to Future Revenue Ratio|HCW Biologics - Forward Price-to-Revenue Multiple|Forward Price to Sales APVO|AIM ImmunoTech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aditxt ADTX|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Market Cap to Expected Sales Ratio calcimedica.com|Forward P/S Multiple AFMD (Affimed N.V.)|Projected Price to Revenue Allakos Inc|HOOK - Price-to-Projected Revenue Ratio|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|ITOS: Forward P/S Multiple|OCEA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Third Harmonic Bio Inc - Future Price to Revenue
